Drugs / 99mTc-Pyrophosphate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05951816 Background | Jul 2023 → Dec 2024 | amyloidosis | University of Tennessee Graduate School of Medicine | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-Pyrophosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951816 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine.” NCT05951816 ↗ |